卡瑞丽珠单抗西段治疗肝细胞癌患者，进展后还要继续使用吗？

概述

1. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul; 19(7):940–52.

2. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non- comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24; 389(10088):2492–502.

3. Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annal Oncol. 2019;30:v874–5.

4. Finn RS, Ryoo BY, Merle P, Kudo M, Bouat- tour M, Lim HY, et al. Pembrolizumab as sec- ond-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020 Jan 20;38(3):193–202.

5. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a ran- domised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064): 56–66.

6. Chen X, Ma L, Wang X, Mo H, Wu D, Lan B, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med. 2019 Feb;16(1):173–81.

声明：本资料当中涉及的接收者仅供参考，请依从医生或其他医疗卫生专业人士的观点或指导。